Rx COMMUNICATIONS Specialists in the life science and healthcare industries Partner-driven -- Senior level counsel on EVERY account Partners have been through up and down market cycles, various political healthcare agendas and technology trends
Rx COMMUNICATIONS Experience with private and public companies – domestic and international Focused on what we do best: Investor Relations and Financial Media Relations Strong Wall Street and media contacts Headquartered in New York City
PRIVATE COMPANIES Services for Private Companies
WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY? Lay the groundwork for future financings and eventual IPO Assist with partnering activities by building corporate awareness Build awareness of disease indications to generate product interest Align company with reputable bankers Become accustomed to working within disclosure rules i.e.; Reg FD
PROVIDING VALUE TO PRIVATE COMPANIES Develop key messages positioned for analysts and investors Develop collateral materials to tell story integrating key messages Target and facilitate introductions to venture capitalists and institutional investors Target and advise on corporate finance team Target and facilitate introductions to sell- side analysts
PROVIDING VALUE TO PRIVATE COMPANIES Build presence on the web Develop story ideas for the media Cultivate reporter interest Introduce to conference circuit Properly position company news Develop company disclosure policy
ACTIVITIES SUROUNDING IPO Assist in the selection of banking team – beginning of quiet period Press release announcing registration for offering Develop roadshow presentation Supplement banker’s list of target institutions Presentation training
ACTIVITIES SURROUNDING IPO “Teach-ins” at banks Roadshow Press release announcing completion of IPO “Welcome letter” to new shareholders Create disclosure policy Quiet period lasts for 25 days following the close of IPO
AFTER-MARKET SUPPORT Need for continual dialogue with shareholders On-going targeting of investors for future financings Increase analyst coverage beyond banking support Fulfill disclosure requirements Crisis communications Strategic media out-reach
GETTING STARTED: FIRST STEPS Strategy session in order to immerse ourselves in corporate story Define key message points Understand perceptions existent in the marketplace Create targeted list of sell-side analysts, venture capitalists and fund managers
GETTING STARTED: FIRST STEPS Review collateral materials Create VIP blast e-mail/fax lists Develop media lists Design action plan
Rx COMMUNICATIONS CAPABILITIES Crisis Communications Mergers and Acquisitions Positioning Strategy Perception Audits Conference Calls Presentation Training Placement Strategy Financial, Trade and Local Media Contacts Slide Presentations Web Site Development
THE Rx TEAM Melody A. Carey, Co-President Founded Rx in 2000 Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc. Director of Investor Relations, The Multicare Companies, Inc. Executive, Noonan/Russo Communications Former healthcare/life sciences investment banker, Kidder, Peabody & Co.
THE Rx TEAM Rhonda Chiger, Co-President Founded Rx in 2000 Senior Managing Director, Global Consulting Practice, Thomson Financial Managed Life Sciences departments for Noonan/Russo and Dewe Rogerson Established London office for healthcare investor relations firm Former Manager, Investor Relations, American Stock Exchange
The Rx Team Eric Goldman, Vice President 25 years experience in public relations and as a media relations strategist specializing in biotechnology, healthcare, technology and consumer products Senior Director and Vice President at GlobalFluency Handled media relations at Spector & Associates and Brouillard Communications, a division of J. Walter Thompson Earned 2 Silver Anvil awards for public relations excellence
THE Rx TEAM Paula B. Schwartz, Senior Vice President Former Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S. Former Vice President, ECOM Consultants, Inc., an investor relations firm Former Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy
Rx COMMUNICATIONS CURRENT CLIENT LIST ADMA Biologics, Inc. (Private) Alexandria Real Estate Equities, Inc. (NYSE: ARE) Alexion Pharmaceuticals Inc. (Nasdaq: ALXN) Bio-Path Holdings, Inc. (OTCQX: BPTH) Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) Complix NV (Private) Galena Biopharma, Inc. (Nasdaq: GALE) Intact Medical Corporation (Private)
Rx COMMUNICATIONS CURRENT CLIENT LIST MAXIMUS, Inc. (NYSE: MMS) MolMed S.p.A. (Milan: MLM) Neovacs, SA (Alternext Paris: ALNEV) Omthera Pharmaceuticals, Inc. (Private) PDI, Inc. (Nasdaq: PDII) Photocure (OSE: PHO) Sigma-Tau Pharmaceuticals, Inc. (Private) TetraLogic Pharmaceuticals (Private) Theratechnologies (TSX: TH)
OURx SUCCESSES Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 95% today. Launched not-for-profit Immune Tolerance Institute resulting in broad coverage in the U.S. including CBS Radio Network, San Francisco Business Times and Drug Discovery News. Garnered coverage for Catalyst Pharmaceutical Partners’ compound for cocaine addiction. Placements included cover stories in Newsweek, Scientific American Mind and NeuroInvestment.
OURx SUCCESSES Designed and implemented assertive investor outreach program for PDI which doubled trading volume and tripled its stock price within nine months. Arranged feature coverage focused on Hodgkins and non-Hodgkins lymphoma for MethylGene with Genetic Engineering News, Pink Sheet, BioCentury and Pharmawire Implemented aggressive IR program for PharmAthene, Inc. which enabled the company to obtain coverage from two new sell-side analysts, garner investments from four new institutional funds and increase trading volume by three-fold within nine months.
OURx SUCCESSES Generated feature articles with Dow Jones Newswire, BioWorld Today, FierceBiotech for the TetraLogic Pharmaceuticals Series C financing. Devised communications campaign to increase visibility of Amorcyte’s enriched bone marrow stem cell therapy by maximizing clinical data presented at American College of Cardiology (ACC) conference. Leveraged key opinion leaders who presented Amorcyte’s data to gain media coverage, surpassing competitors with later stage clinical data and larger operating budgets. News coverage included: Reuters, CBS Radio Network, Start-Up Magazine & Pharmawire.
OURx SUCCESSES Generated news coverage with Dow Jones Newswire, Wall Street Journal.com, Drug Discovery & Development for launch of Neovacs autoimmune disease therapeutics. Developed compelling key messages and arranged media interviews surrounding ZIOPHARM Oncology sarcoma clinical trials resulting in news coverage from Bloomberg Television, Reuters Newswire, BusinessWeek, Associated Press, Wall Street Journal and Forbes.
OURx SUCCESSES Rx Communications Group was honored with the 2008 Stevie Award for Best Investor Relations Program for work on behalf of specialty pharmaceutical company, NexMed, Inc. We are pleased to announce that Rx Communications has been selected by PR Week as a finalist for Boutique PR Agency of the Year Rx Communications was named Best Small PR Agency by League of American Communications Professionals
OURx SUCCESSES Rx Communications was honored with the 2002 SABRE Awards Certificate of Excellence for Building a North American Investor Base for client Syngenta AG. We are also pleased to share that our work for ImpactRx has won an Honorable Mention Award in LACP’s (League of American Communications Professionals) 2002 Publicity Campaign Competition. Rx Communications received an honorable Mention Award from PR News, as part of the PR News Platinum PR Awards 2003. The award was issued in the Financial/Investor Relations category, for the company's work on behalf of Genaissance Pharmaceuticals, Inc.
WHY Rx COMMUNICATIONS? Specialist industry knowledge and expertise Personal attention from Rx partners Decades of experience in strategic counsel and implementation of financial public relations programs Unique niche in working with private companies Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions “The Street” knows and trusts us
For Additional Information: Rx Communications Group, LLC 445 Park Avenue 10 th Floor New York, NY 10022 (917) 322-2568 www.RxIR.com